Bide Pharmatech (SH:688073)2025-02-25 07:50Financial Performance - Total revenue for 2024 reached RMB 1,102.01 million, a year-on-year increase of 0.93%[4] - Net profit attributable to shareholders of the parent company was RMB 122.79 million, up 12.07% compared to the previous year[4] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses decreased by 11.20% to RMB 108.79 million[4] - Basic earnings per share increased by 14.05% to RMB 1.38[4] - The weighted average return on equity rose by 0.76 percentage points to 6.04%[4] Assets and Equity - The company's total assets at the end of 2024 were RMB 2,418.00 million, reflecting a slight increase of 0.12% from the beginning of the year[5] - Shareholders' equity attributable to the parent company decreased by 2.72% to RMB 2,032.63 million[5] Strategic Focus - The company is focusing on international expansion and digital transformation to enhance operational efficiency and revenue growth[9] Financial Data Integrity - There were no financial data or indicators with a change of 30% or more during the reporting period[10] - The financial data presented are preliminary and subject to final audit in the annual report[11]